Slides
Page 1
BALAJI AMINES LIMITED Investor Presentation | Q2 & H1 FY27 INDIA FIRST. Building What India Needs Before India Asks for It.
Page 2
Disclaimer 2 This presentation and the accompanying slides (the “Presentation”), which have been prepared by Balaji Amines Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
Page 3
FINANCIAL HIGHLIGHTS Q2 & H1 FY27
Page 4
Key Highlights of the Quarter Q2 FY27 reflected resilient execution and steady progress on our strategic priorities. On a consolidated basis, Total Revenue grew 36% year-on-year to ₹472 crore, EBITDA rose 58% to ₹106 crore with a margin of 22%, and PAT increased 82% to ₹67 crore. For H1 FY27, consolidated PAT nearly doubled to ₹146 crore. Volumes were dented by external factors, including raw material availability and delayed supply chains, yet our stable product portfolio kept the top line resilient, with standalone volumes improving 11% over Q1. Commercial production commenced at our upgraded Acetonitrile facility, and with PESO approval of DME road tanker valves, we are now building our DME customer network. N-Methyl Morpholine is our next product for commercialisation, while BSCL's Unit-I brownfield expansion is on track for commissioning by end-FY27 and the Unit-II HCN, NaCN and EDTA project is targeted for Q4 FY27. With a visible expansion roadmap and disciplined execution, we remain confident of driving sustainable growth and long-term shareholder value. 4 Mr. Dundurapu Ram Reddy Managing Director
Page 5
Financial highlights – Q2 FY27 5 STANDALONE Total Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) EBITDA & PAT MARGIN (%) CONSOLIDATED Total Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) EBITDA & PAT MARGIN (%) 18% 26% 24% 10% 17% 16% Q2FY26 Q1FY27 Q2FY27 EBITDA PAT 316 429 434 Q2 FY26 Q1FY27 Q2 FY27 57 110 103 Q2FY26 Q1FY27 Q2FY27 348 461 472 Q2FY26 Q1FY27 Q2FY27 67 121 106 Q2FY26 Q1FY27 Q2FY27 31 72 69 Q2FY26 Q1FY27 Q2FY27 37 78 67 Q2FY26 Q1FY27 Q2FY27 19% 26% 22% 11% 17% 14% Q2FY26 Q1FY27 Q2FY27 EBITDA PAT
Page 6
Financial highlights – H1 FY27 6 STANDALONE Total Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) EBITDA & PAT MARGIN (%) CONSOLIDATED Total Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) EBITDA & PAT MARGIN (%) 19% 25% 11% 16% H1 FY26 H1 FY27 EBITDA PAT 643 863 H1 FY26 H1 FY27 121 213 H1 FY26 H1 FY27 715 933 H1 FY26 H1 FY27 131 227 H1 FY26 H1 FY27 71 141 H1 FY26 H1 FY27 74 146 H1 FY26 H1 FY27 18% 24% 10% 16% H1 FY26 H1 FY27 EBITDA PAT
Page 7
Standalone Statement of Profit & Loss 7 Particulars (Rs.Crs.) Q2FY27 Q2FY26 Y-o-Y Q1FY27 Q-o-Q H1 FY27 H1 FY26 Total Revenue 434 316 37.33% 429 1.24% 863 643 Total Raw Material 239 177 237 476 357 Employee Expenses 24 18 24 48 37 Other Expenses 68 65 58 126 128 EBITDA 103 57 81.39% 110 -5.71% 213 121 EBITDA Margin (%) 24% 18% 26% 25% 19% Depreciation 13 12 12 24 23 EBIT 91 45 99.40% 98 -7.58% 189 98 EBIT Margin (%) 21% 14% 23% 22% 15% Finance Cost 0 0 0 0 1 Profit before Tax 90 45 100.83% 98 -7.55% 188 97 Profit before Tax(%) 21% 14% 23% 22% 15% Tax 22 14 26 47 26 Profit After Tax 69 31 118.55% 72 -4.73% 141 71 PAT Margin (%) 16% 10% 17% 16% 11% EPS (As per Profit after Tax) 21.21 9.71 22.27 43.48 21.99
Page 8
Consolidated Statement of Profit & Loss 8 Particulars (Rs.Crs.) Q2FY27 Q2FY26 Y-o-Y Q1FY27 Q-o-Q H1 FY27 H1 FY26 Total Revenue 472 348 35.78% 461 2.28% 933 715 Total Raw Material 265 185 253 518 397 Employee Expenses 26 19 26 52 40 Other Expenses 75 76 61 136 147 EBITDA 106 67 58.46% 121 -12.72% 227 131 EBITDA Margin (%) 22% 19% 26% 24% 18% Depreciation 15 14 14 29 28 EBIT 91 53 72.36% 108 -15.77% 198 102 EBIT Margin (%) 19% 15% 23% 21% 14% Finance Cost 1 1 1 3 2 Profit before Tax 89 52 72.96% 106 -15.92% 196 101 Profit before Tax(%) 19% 15% 23% 21% 14% Tax 22 15 28 50 27 Profit After Tax 67 37 81.85% 78 -13.63% 146 74 PAT Margin (%) 14% 11% 17% 16% 10% EPS (As per Profit after Tax) 20.76 10.67 23.13 43.89 22.39
Page 9
Consolidated Balance Sheet Statement 12 ASSETS (Rs. Crs.) Sep-26 Mar-26 (1) NON-CURRENT ASSETS (a) Property, plant & equipment 1,160 1,035 (b) Capital work-in-progress 513 512 (c) Other Intangible assets 3 3 (d) Intangible asset under development 0 0 (e) Investment Property 4 5 (f) Right-of-use assets 0 0 (g) Financial Assets (i) Investments 0 0 (ii) Other Financial Assets 12 15 (h) Other Non - current assets 31 232 Sub Total (A) 1,723 1,802 (2) CURRENT ASSETS (a) Inventories 282 247 (b) Financial Assets (i) Trade receivables 389 346 (ii) Cash and cash equivalents 53 74 (iii) Bank Balances other than (iii) above 175 197 (iv) Other (to be specified) 0 0 (c) Current tax assets (net) 0 0 (d) Other current assets 109 76 Sub Total (B) 1,008 941 Total Assets (A+B) 2,731 2,743 EQUITY AND LIABILITIES (Rs. Crs.) Sep-26 Mar-26 EQUITY (a) Equity Share capital 6 6 (b) Other equity 2,077 1,970 Attributable to owner of parent 2,083 1,976 Non controlling interest 179 175 Sub Total (C) 2,262 2,152 LIABILITIES (1) Non-Current Liabilities (a) Financial Liabilities (i) Lease Liabilities 0 0 (ii) Borrowings 129 65 (iii) Other Financial Liabilities 5 5 (b) Provisions 3 3 (c) Deferred Tax Liabilities (Net) 122 114 (d) Other Non-Current Liabilities 1 1 Sub Total (D) 261 189 (2) Current Liabilities (a) Financial liabilities (i) Lease Liabilities 0 0 (ii) Borrowings 32 68 (iii) Trade Payables 70 85 (iv) Other Financial Liabilities 81 222 (b) Other current liabilities 10 15 (c) Provisions 2 1 (d) Current tax liabilities (Net) 14 11 Sub Total (E) 208 402 Total Equity & Liabilities (C+D+E) 2,731 2,743
Page 10
Consolidated Cash Flow Statement 1013 Cash Flow Statement for half year ended (in Rs. Crore) Sep-26 Sep-25 Profit before Tax 196 101 Adjustment for Non-Operating Items 28 22 Operating Profit before Working Capital Changes 224 122 Changes in Working Capital -143 -85 Cash Generated from Operations 80 38 Less: Direct Taxes paid -26 -16 Net Cash from Operating Activities 54 22 Cash Flow from Investing Activities -67 -115 Cash Flow from Financing Activities -9 -17 Net increase/ (decrease) in Cash & Cash equivalent -21 -110 Add: Cash and cash equivalents 74 149 Cash and cash equivalents as at 30th September, 2026 53 39
Page 11
COMPANY OVERVIEW
Page 12
At a Glance 12 12 One of India’s Largest Aliphatic amines manufacturers 35+ years of manufacturing expertise 4,02,600+ MTPA Installed Capacity India’s First Commercial DME Manufacturer 40+ Products 65+ International clients Debt free Standalone balance sheet Driven by innovation and import substitution, Balaji Amines continues to strengthen its specialty chemicals portfolio through differentiated products and disciplined expansion. WE BUILT INDIA’s 1st INDIGENOUS TECHNOLOGY FOR MANUFACTURING ALIPHATIC AMINES 50+ Countries served Core processes Developed through Inhouse- R&D
Page 13
13 Corporate Structure Manufacturing Locations Strong multi-location manufacturing base Speciality Chemical Units (BSCL) Focus on High- Value Speciality Chemicals Operations across Maharashtra & Telangana Strategically located for scale and efficiency Balaji Amines Ltd Unit I Solapur Unit II Telangana Unit III Solapur Unit IV Solapur BALAJI AMINES (Core Manufacturing) Leading manufacturer of aliphatic amines and speciality chemicals BSCL Unit I Solapur BSCL Unit II Solapur BALAJI SPECIALITY CHEMICALS LTD ( Subsidiary) Expanding the portfolio of speciality for high- growth industries Hospitality Division Hotel Balaji Sarovar 4 2
Page 14
14 Manufacturing Locations – Built for Scale BALAJI AMINES Unit I – Solapur Key Products: • Methylamines • Ethyl amines • Morpholine • Isopropyl amines (MIPA) • Dimethylamine (DMA) • Dimethyl Acetamide • Dimethyl Urea • Choline Chloride and other derivatives • Dimethyl Amino Ethanol (DMAE) • Diethyl Amino Ethanol (DEAE) Unit III – Solapur Key Products: • Dimethyl Formamide • Morpholine • Acetonitrile • Polyvinylpyrrolidone • Methylamines • Dimethyl Amine Hydrochloride • Gamma-Butyrolactone • N-Methyl Pyrrolidone • 2-Pyrrolidone Unit IV – Solapur Key Products: • Ethyl amines • Methylamines • N-Butylamine • Dimethyl Carbonate (DMC) • Propylene Carbonate (PC) • Propylene Glycol (PG) • Dimethyl Ether (DME) • N-Methyl Morpholine (NMM) • ISO 9001:2015 Quality Management Systems • ISO 14001:2015 Environmental Management • ISO 45001:2018 Occupational Health & Safety • WHO-GMP Required for pharma-linked regulated markets • Three- Star Export House • REACH • FAMI-QS BALAJI SPECIALITY CHEMICALS LTD (BSCL) BSCL Unit I Key Products Include: • EDA • DETA • TETA • Piperazine • AEEA • AEP BSCL Unit II Key Products Include: • HCN • Sodium Cyanide • EDTA • EDTA – 2Na • Cyanation R&D plant • ISO ISO 9001:2015 • ISO 14001:2015 • ISO 45001:2018 • REACH –EDA & DETA • Two-Star Export House Certifications: Certifications: Unit II – Telangana Key Products: • Dimethylamine (DMA) • Hydrochloride (HCl)
Page 15
Executing the Next Growth Phase 15 Commissioning key projects while advancing the next phase of speciality chemicals expansion. As new capacities come on stream and ongoing projects progress toward commissioning, Balaji Amines is well positioned to leverage emerging opportunities in speciality chemicals, supporting long-term growth and value creation. DME Successfully Commissioned (Q1 FY27) STATUS: OPERATIONAL • 100,000 TPA DME plant commissioned in Q1 FY27, marking India's first commercial-scale DME manufacturing facility. • Creates exposure to clean fuel, LPG blending and Aerosol as a propellant application in healthcare and personal care sectors, strengthening the Company's wide product portfolio. ACN Commercialized | NMM Under Execution STATUS: ACN (OPERATIONAL) NMM (UNDER EXECUTION) • Acetonitrile (ACN): Commercial production commenced at the expanded Unit III facility, incorporating an improved manufacturing process to strengthen cost competitiveness. • N-Methyl Morpholine (NMM): The 5,000 TPA project is progressing, with commissioning expected during FY27, further broadening the Company's specialty chemicals portfolio. R&D Mechanism IN-HOUSE R&D PROGRAMME • Higher utilization of recently commissioned capacities expected to improve operational efficiency. • Ongoing capacity additions continue to strengthen the Company's speciality chemicals platform.
Page 16
16 • Greenfield project comprising HCN, Sodium Cyanide, EDTA & EDTA-2Na under execution. • Commissioning targeted by end-FY27, creating a new speciality chemicals platform for pharmaceuticals, agrochemicals, mining and water treatment. STATUS: PLANNED STATUS: UNDER EXECUTION • EDA derivatives project (DETA, TETA, PIP , AEEA & AEP) progressing as planned. • Commissioning targeted during FY27, expanding the company’s portfolio of high-value speciality amines. CYANATION R&D PROCESS IN-HOUSE R&D PROGRAMME • Tri Ethyl Ortho Formate (TEOF) identified as the next phase of expansion. • Expands BSCL's value-added product portfolio and supports future commercialization. • Translating complex cyanide chemistry processes into commercial production to replace current import dependencies for domestic pharma and agrochemical sectors BSCL Unit II – Phase I Progress Driving import substitution through phased commissioning of high-value speciality chemical platforms BSCL – Building Future Capabilities STATUS: UNDER EXECUTION BSCL Unit I – EDA Derivatives Platform Phase II Expansion BSCL is progressing through a phased expansion program that strengthens Company’s speciality chemicals platform, enhances import substitution capabilities, and creates long-term growth opportunities across regulated and industrial markets.
Page 17
Positioned for Sustainable Growth 17 Balaji Amines is transitioning from an amines manufacturer to a speciality chemicals platform, driven by import substitution, EV-linked products, strong balance sheet strength and a large earnings-led capex payoff cycle. • ₹1000 Cr+ expansion cycle nearing completion on consolidated basis • FY27 Profit is expected to grow with a guidance at 200-300 bps. • Earnings acceleration expected as DME and ACN are commercialized and NMM and BSCL projects ramp up in the ensuing FY Capex-to-Cashflow Inflection • Only Indian producer of Electronic Grade DMC for EV battery applications • India's first commercial-scale DME (100 KTPA) manufacturer • The first and sole domestic manufacturer of N-Methyl-2- Pyrrolidone (NMP) in India • Upcoming HCN, Sodium Cyanide and EDTA projects further strengthen import- replacement portfolio Unique Import-Substitution Franchise • Standalone business remains debt-free • Expansion funded through internal accruals • Strong balance sheet with ₹2,262 Cr net worth provides downside protection Growth Without Leverage • Indigenous technology with no royalty burden • Backward integration and methylamines scale-up driving cost leadership • EBITDA margin targeted at 22- 23% in FY27 vs ~20% in FY26 Structural Margin Expansion
Page 18
Product Existing Licensed Capacity (TPA) Proposed Capacity (TPA) Total Capacity after Expansions (TPA) Application Areas BSCL – Scaling Speciality Chemicals 18 Ethylenediamine 37,350 - 37,350 Pharma, Fungicides, Pesticides, Polymers and Coatings Piperazine 4,050 3,300 7,350 Pharma, Oilfield Diethylenetriamine 3,150 8,900 12,050 Coatings, Polymers, Pharma Mixture of Amines (AEP, AEEA,HEP) 780 1,000 1,780 Multiple Industries Mixture of TEPA & PEHA - 1,000 1,000 Epoxy curing agents, Polyamide resins, Corrosion inhibitors, Adhesives and Sealants Hydrogen Cyanide - 10,000 10,000 Pharmaceuticals and agrochemicals, Mining chemicals Sodium Cyanide (100% Pellet) - 12,000 12,000 Gold and silver mining, Electroplating, Chemical intermediates Triethylenetetramine (TETA) - 3,000 3,000 Epoxy curing agents, Polyamide resins, Fuel additives, Corrosion inhibitors Ammonium Sulphate - 7,500 7,500 Fertilizers, Industrial applications, Chemical intermediates Sodium Sulphate - 5,300 5,300 Detergents and soaps, Glass manufacturing, Textile processing, Pulp and paper Ethylene Diamine Tetra Acetic Acid (EDTA) & Ethylene Diamine Tetra Acetic Acid Disodium (EDTA-2Na) - 5,000 5,000 Pharmaceuticals, Detergents and cleaning formulations Total 45,330 57,000 1,02,330 Balaji Speciality Chemicals
Page 19
Product Existing Licensed Capacity (TPA) Proposed Capacity (TPA) Total Capacity after Expansions (TPA) Application Areas Manufacturing Capacity to Capture Future Demand 19 Methyl Amine 88,000 - 88,000 Pharma, Agro, Dye & Rubber Ethyl Amine 22,500 - 22,500 Pharma, Agro, Dye & Rubber DMAHCL / DMAC 31,000 7,500 38,500 Pharma Choline Chloride 60% (Corn Cob) 6,000 - 6,000 Animal Feed Choline Chloride 75% & 98% 6,000 - 6,000 Animal Feed 2P / NEP 33,000 - 33,000 Pharma, Agro, Petro, Dyes, Paints NMP - Pharma, Agro, Petro, Dyes, Paints GBL - Pharma, Agro, Petro, Dyes, Paints DMU 3600 - 3600 Pharma, Textile, Agro DMAE / DEAE 2,000 - 2,000 Cosmetics Morpholine 10,000 - 10,000 Pharma, Agro, Dyes, Paints, Textile, Rubber Other HCL'S 750 - 750 Animal Feed DMF 30,000 - 30,000 Pharma, Agro, Polymers, Petro, Dyes, Paints Acetonitrile (ACN) 18,000 - 18,000 Pharma, Petro, Textile, Plastics PVP K-30 750 - 750 Pharma, Agro, Cosmetics Di-methyl Carbonate (DMC) 15,000 - 15,000 Pharma, Polycarbonate, Automobiles Propylene Glycol (PG) 15,000 - 15,000 Food Grade Dimethyl Ether (DME) 1,00,000 - 1,00,000 Replacement of LPG n-Butylamine 15,000 - 15,000 Pharma, Agro N-Methyl Morpholine (NMM) - 5,000 5,000 Pharma , Oil & Gas MIPA/DIPA 6,000 - 6,000 Pharma, Agro, Dyestuff Total 4,02,600 12,500 4,15,100 Balaji Amines
Page 20
A Diversified Product Portfolio 20 Amines Amine Derivatives Speciality & Other Chemicals Description Products Application • The foundation of Balaji Amines' integrated value chain, supplying essential building blocks for a wide range of downstream chemicals. • The segment serves diverse industries through high-quality, vertically integrated manufacturing. • Value-added products that expand the Company's presence across pharmaceutical, agrochemical and industrial applications. • This segment enhances product diversification while increasing value addition.. • A high-value portfolio serving advanced applications across pharmaceuticals, • EV batteries and speciality industries. Driven by indigenous technology and import substitution, the segment supports Balaji's future growth strategy. • Mono Methyl Amine (MMA) • Di Methyl Amine (DMA) • Tri Methyl Amine (TMA) • Mono Ethyl Amine (MEA) • Di Ethyl Amine (DEA) • Tri Ethyl Amine (TEA) • N-Butylamine, Isopropylamine • Dimethyl Amino Ethanol • Diethyl Amino Ethanol • DMAC • DMA HCL • DMU • Corn Cob • Aqueous Solution • Morpholine • Acetonitrile (ACN) • DME • DMF • NMP • GBL • DMC, Gamma-butyrolactone • Propylene Carbonate (PC) • Propylene Glycol (PG) • 2-Pyrrolidone, NEP, PVPK • Pharma • Agro • EV Battery • Photographic chemicals • Rocket fuel • Dyestuff intermediates • Rubber chemicals, etc • Pharma • Pesticides • Performance chemicals • Speciality chemicals • Animal/poultry feed additive etc. • Production of Water Treatment chemicals and pesticide formulations • Fuel Additives and EV Battery Chemicals • Solvents across industries like pharmaceuticals, petrochemicals, dyes, Agro and paint industries • Formulations and Intermediates in pharmaceuticals • Lubricant Manufacturing
Page 21
Integrated Across the Value Chain 21 End Markets Pharma Agrochemicals EV Batteries Industrial Electronics Energy Speciality Chemicals Morpholine DME, DMF NMP , NEP , GBL ACN 2P , PVPK DMC , PC , PG DMAE DEAE Amine Derivatives DMAHCL DMAC DMU Choline Chloride Core Amines Methylamine Ethylamine Isopropylamine N Butylamine Feedstock Methanol Ethanol Ammonia, etc. Vertical Integration Complete control from raw materials to speciality chemicals, enabling cost efficiency, quality consistency and supply reliability 90 - 95% of domestic demand met For select key products, Balaji Amines' domestically developed processes. BAL demonstrating supply chain leadership at national scale, not just commercial scale Diversified End Markets Serving multiple high-growth industries including pharmaceuticals, agrochemicals, EV batteries, electronics and industrial chemicals
Page 22
About Balaji Speciality Chemicals (BSCL) 22 Balaji Speciality Chemicals Limited (BSCL), a 55% subsidiary of Balaji Amines Limited, is our strategic platform for high-value speciality chemicals. Located in Solapur, Maharashtra, BSCL commenced commercial operations in 2019 and is strengthening India's import substitution capabilities through speciality amines and derivatives. It obtained Mega project status by Government of Maharashtra. Strategic Growth Platform Key Highlights Sole Indian manufacturer of key speciality amines and derivatives – EDA, DETA, PIP , AEEA and AEP . Why BSCL Matters REACH is a European Regulation and is an acronym for the Registration, Evaluation, Authorisation and Restriction of Chemicals. REACH registrations* for EDA, DETA and AEEA strengthen our access to regulated international markets. A key growth engine supporting Balaji Amines’ long-term growth strategy and value creation. 45,330 MTPA Installed manufacturing capacity Expanding Capacity – 57,000 MTPA Import Substitution Manufactures high-value speciality amines and derivatives Global Presence Exports to USA, Europe and other global markets Addition of HCN, NACN and EDTA Plants
Page 23
Trusted by Industry Leaders Across the Globe 23 Amines Amine Derivatives Speciality & Other Chemicals
Page 24
Serving Diverse End Markets 24 Industry Wise – Revenue Breakup 63% 28% 3% 6% Pharma Agro Oil & Gas Others
Page 25
Expanding Global Footprints 25 UK US Argentina Canada Israel India Pakistan Bangladesh Oman Germany Italy Egypt South Africa Korea Taiwan Spain France Belgium Netherlands Norway Poland Ukraine Mexico Brazil Australia China Japan Turkey Finland Indonesia Switzerland Sri Lanka Russia Malaysia Singapore Bahrain Jordan Guatemala Colombia Costa Rica Thailand Morocco Peru Venezuela Philippines Saudi Arabia Vietnam Ireland Qatar Kuwait Denmark Country OUR EXPORT PRESENCE Delivering our products to 50+ countries across the world
Page 26
HOTEL BALAJI SAROVAR
Page 27
About Balaji Sarovar Premiere Hotel 27 Hotel project has resulted in substantial cash flow savings • Commenced Operations in October 2013 Hotel Balaji Sarovar Premier is the only 5 star hotel in Solapur • Invested Rs. 110 crore in the Hotel Project via mix of Debt and Equity • Tied up with Sarovar Group for the Management of the Hotel on Management Fee + Revenue Share model • Solapur is an important Tourist hub owing to its close proximity to Pandharphur, Tuljapur, Siddeshwar Temple, Ganagapur, Bijapur and Akkalkot • Solapur attracts millions of Tourists and pilgrims every year
Page 28
Balaji Sarovar Premiere – Q2 & H1 FY27 Operating Matrix 28 Renowned Five Star Hotel In the City of Solapur 129 Rooms Constitutes 1.52% of Total Revenue Rs. 717 Lakhs Revenue from Hotel Division Rs. 4922 ADR 67% Occupancy Rate Rs. 3288 RevPAR ADR: Average Daily Rate RevPAR: Revenue per Available Room
Page 29
HISTORICAL PERFORMANCE
Page 30
Consolidated Performance Highlights 30 1671 1430 1454 Revenue (Rs. Crs) 20262024 2025 353 265 294 EBITDA (Rs. Crs.) 21 18.5 20.24 EBITDA Margin (%) 14 11.1 11.64 PAT Margin (%) 13.5 8.6 9.17 ROE (%) 20262024 2025 232 159 169 PAT (Rs. Crs.) 20262024 2025 20262024 2025 20262024 2025 20262024 2025
Page 31
Strong Core ROCE Profile 31 Particulars (Rs. Crs.) FY26 FY25 Consolidated Debt 133 11 Consolidated Networth 2152 2018 Total Capital Employed 2285 2029 Less: Investment in Hotel Balaji Sarovar & Others 95 117 Add: Loss in Hotel Balaji Sarovar & Others 35 43 Less: Investments in Capital Work in Progress in Greenfield project (Unit 4), Plant in Unit 3, Unit 1 187 173 Less: Investments by BSCL in Capital Work in Progress in Brownfield project (Unit 1) & Greenfield project (Unit 2) 343 116 Core Chemical Business Capital Employed (A) 1695 1666 EBIT on Consolidated Basis 238 217 Less: EBIT Loss Specific to Hotel Balaji Sarovar & Others 11 10 Core Chemical Business EBIT (B) 227 207 ROCE for Core Chemical Business (B/A) 13% 12% ROCE at Consolidated Entity Level 14% 11% Core chemical business continues to deliver a superior RoCE, reflecting the strong fundamentals and manufacturing capabilities that Balaji Amines has built over the years. The capital work-in-progress at the subsidiary Balaji Speciality Chemicals Ltd (BSCL) amounts to Rs. 438.17 crore, and is allocated towards 1) A greenfield expansion to manufacture HCN, NaCN, EDTA, EDTA-Na, and other advanced chemical products 2) Brownfield expansions for EDA-based chemical production The capital work-in-progress across various units, totalling to Rs. 78.54 crore, pertains mainly to N-Methyl Morpholine (NMM) plant currently under development. Quarter and half year ended September 2026:
Page 32
Consistent Dividend Payout 32 Particulars (Rs. per share) FY21 FY22 FY23 FY24 FY25 FY26 Consolidated Book Value 281 406 524 584 623 664 Consolidated EPS 74 114 100 63 49 52 Dividend 4.00 6.00 10.00 11.00 11.00 11.00 FY21 FY22 FY23 FY24 FY25 200% 300% 500% 550% 550% FY26 550%
Page 33
LEADERSHIP & RESPONSIBILITY
Page 34
Highly Experienced Management Team 34 MR. A. PRATHAP REDDY • Civil Engineer by Education. Incorporated BAL in 1988 • BAL's continuing success is a testimony to his entrepreneurial skills. • His vision has made BAL today as one of the leading players in chemical industry. • Honored with “Best CEO of emerging companies” in Chemical Sector. Executive Chairman MR. D. RAM REDDY • 45 years of experience across various businesses. • Focused on establishing customer and supplier's relationship with leading buyers and suppliers • Responsible for the supply chain, sales and marketing • Has been awarded the Lifetime Achievement Award from Punyashlok Ahilyadevi Holkar Solapur University in July`24 Managing Director MR. N. RAJESHWAR REDDY • Commerce Graduate having over 48 years of experience across industries • Instrumental in project commissioning with indigenous approach to improve return profile • Responsible for operations in Solapur Whole Time Director MR. A. SRINIVAS REDDY • Post Graduate in Computer Science and completed Executive Management Programme at ISB Hyderabad. • More than 28 years experience in multiple Project Management Roles • He is presently responsible for projects Whole Time Director & CFO
Page 35
Awards & Certificates – A Testimony of our capabilities 35 ISO Certificate Three Star Export House ISO Certificate ISO 9001 : 2015 Certificate Certificate of Merit - CHEMEXCIL First Award - CHEMEXCIL WHO GMP Certificate BEST CEO (CHEMICAL INDUSTRY) AWARD TO SHRI ANDE PRATHAP REDDY BY BUSINESS TODAY GROUP
Page 36
Awards & Recognition - A Testimony of our capabilities 36 Balaji Amines Limited has received the Best Project Award in the area of Healthcare, under the Large Enterprise category by Rotary India, National CSR Awards 2025 Balaji Amines Limited has been awarded as Sustainability Leader of the Year in Chemicals at FICCI Chemicals and Petrochemicals Awards 2025 by FICCI (Federation of Indian Chambers of Commerce and Industry Balaji Sarovar Premiere, has been honoured with the Food Connoisseurs India Award for Restaurant Serving the best Chinese cuisine– 2026 Balaji Amines Limited has been conferred with the Narayan Meghaji Lokhande Occupational Safety & Health Award 2026 by the Directorate of Industrial Safety and Health (DISH), Government of Maharashtra. On October 8, 2025, Balaji Amines Limited bagged the Western Zone Award in the Large-Scale Enterprise category for its outstanding work in the Healthcare Sector
Page 37
ESG & CSR Initiatives 37 Constructed Classroom at ZPHS Chengal School, Mandal Bhimgal, Nizamabad, dt. 04.01.2025 Construction of Toilet Block at Indira Kale Prashala, Jalkotwadi, dt. 25.03.2025 Distributed Sanitary Napkin Incinerator and Vending Machine at Vishwabhushan Vidyalay, Solapur dt.30.09.2024 Distribution of Helmets for Highway Safety Squad Sambhaji Nagar dt. 17.02.2025 Distribution of SSC Board Exam Books in Solapur and Dharashiv dt. 15.01.2025 MPSC & UPSC competitive Examination Books and 1 Public System to Telugu Bhasha Abhivrudhhhi Sarvajanik Granthalayam, Solapur dt. 20.08.2024 Sponsorship to Sandhyarani Bandgar Tennis Player ITF Team Championship Turkey 09-03-2025
Page 38
cs@balajiamines.com www.balajiamines.com Balaji Amines Limited CIN-L24132MH1988PLC049387 Investor Relations Team Email- cs@balajiamines.com www.balajiamines.com COMPANY : INVESTOR RELATIONS ADVISORS : Mr. Nikunj Seth nikunj.seth@in.mpms.mufg.com MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services THANK YOU Ms. Sakshi Mehta sakshi.mehta@in.mpms.mufg.com Meeting Request Link Link